GlassScriptPhysician profile
John Eric Stupka
NPI 1407936024
$1,784.08
in general payments reported to CMS, 2019-2025
21 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $28.46 · 2021: $30.91 · 2022: $76.53 · 2023: $476 · 2024: $678 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.04 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $400.87 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.19 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $308.44 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $223.45 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $107.95 | 2019 | |
| Philips North America LLC | $67.93 | 2021-2023 | |
| Tactile Systems Technology INC | $62.07 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Merck Sharp & Dohme LLC | $35.46 | 2019-2024 | Winrevair |
| Genzyme Corporation | $25.80 | 2024 | |
| Baxter Healthcare | $22.86 | 2022 | |
| Pulmonx Corporation | $22.48 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Monaghan Medical Corporation | $21.43 | 2023 | Aerobika |
| Mylan Specialty L.P. | $21.27 | 2019 | |
| Vapotherm INC | $20.47 | 2024 | Vapotherm |
| Ani Pharmaceuticals, INC. | $20.17 | 2024 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $20.13 | 2024 | Tyvaso |
| Itamar Medical INC | $19.77 | 2023 | Watchpatone |
| Regeneron Healthcare Solutions, INC. | $19.34 | 2024 | Dupixent |
| Insmed, INC. | $19.30 | 2024 | Arikayce |
| Electromed, INC. | $14.88 | 2025 | Smartvest |
| Amgen INC. | $12.82 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stupka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.